COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,796 Articles (22,527 medRxiv, 8,269 bioRxiv)

Most recent first Previous |  Page 646: Articles 6451-6460  | Next

An Agent-Based Model for COVID-19 in Bangladesh
Farheen, F., Shamil, M. S., Jony, S. S. R., Ahmad, Z., Sojib, K. H., Chowdhury, A., Arifin, S. N., Sania, A., Rahman, M. S.
10.1101/2022.07.24.22277974 — Posted: 2022-07-25
High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cells.
Phetsouphanh, C., Khoo, W. H., Jackson, K., Klemm, V., Howe, A., Aggarwal, A., Akerman, A., Milogiannakis, V., Ospina Stella, A., Rouet, R., Schofield, P., Faulks, M. L., Law, H., Danwilai, T., Starr, M., Munier, C. M. L., Christ, D., Singh, M., Croucher, P. I., Brilot-Turville, F., Turville, S., Phan, T. G., Dore, G. J., Cunningham, P., Matthews, G. V., Kelleher, A. D., Zaunders, J. J.
10.1101/2022.07.22.22277947 — Posted: 2022-07-24
Predicting intention to vaccinate against COVID-19 in older Syrian refugees in Lebanon: findings from a multi-wave study
El Salibi, N. J., Abdulrahim, S., El Haddad, M., Abi Zeid, B., Alawieh, M., Ramadan, Z., Ghattas, H., McCall, S. J.
10.1101/2022.07.23.22277948 — Posted: 2022-07-24
Vaccination strategies impact the probability of outbreak extinction: a case study of COVID-19 transmission
Jitsuk, N. C., Chadsuthi, S., Modchang, C.
10.1101/2022.07.23.22277952 — Posted: 2022-07-24
A Randomised -Controlled Phase 2 trial of Molnupiravir in Unvaccinated and Vaccinated Individuals with Early SARS-CoV-2
Khoo, S. H., FitzGerald, R., Saunders, G., Middleton, C., Ahmed, S., Edwards, C. J., Hasdjiyiannaskis, D., Walker, L., Lyon, R., Shaw, V., Mozgunov, P., Periselneris, J., Woods, C., Bullock, K., Hale, C., Reynolds, H., Downs, N., Ewings, S., Buadi, A., Cameron, D., Edwards, T., Knox, E., Donovan-Banfield, I., Greenhalf, W., Chiong, J., Lavelle-Langham, L., Jacobs, M., Painter, W., Holman, W., Lalloo, D. G., Tetlow, M., Hiscox, J. A., Jaki, T., Fletcher, T., Griffiths, G., AGILE CST-2 Study Group
10.1101/2022.07.20.22277797 — Posted: 2022-07-24
Evaluation of Seropositivity after Standard Doses of Vaccination against SARS-CoV-2 in Early Breast Cancer Patients Receiving Adjuvant Treatment
Kim, J., Chang, E., Park, S. Y., Lee, D.-W., Kang, C. K., Choe, P. G., Kim, N. J., Oh, M.-d., Park, W. B., Lee, K.-H., Im, S.-A.
10.1101/2022.07.23.22277888 — Posted: 2022-07-24
Pin-pointing the key hubs in the IFN-gamma pathway responding to SARS-CoV-2 infection
Toro, A., Lage-Vickers, S., Bizzotto, J., Vilicich, F., Sabater, A., Pascual, G., Ledesma-Bazan, S., Sanchis, P., Ruiz, M. S., Arevalo, A. P., Porfido, J. L., Seniuk, R., Labanca, E., Anselmino, N., Navone, N., Alonso, D. F., Vazquez, E., Crispo, M., Cotignola, J., Gueron, G.
10.1101/2022.07.22.22277931 — Posted: 2022-07-23
Cervical cancer screening improvements with self- sampling during the COVID-19 pandemic
Elfström, M., Dillner, J.
10.1101/2022.07.19.22277806 — Posted: 2022-07-23
Synergism of interferon-beta with antiviral drugs against SARS-CoV-2 variants
Bojkova, D., Stack, R., Rothenburger, T., Kandler, J. D., Ciesek, S., Wass, M. N., Michaelis, M., Cinatl, J.
10.1101/2022.07.22.501169 — Posted: 2022-07-22
COVID-19 vaccine effectiveness against mortality and risk of death from other causes after COVID-19 vaccination, the Netherlands, January 2021- January 2022
de Gier, B., van Asten, L., Boere, T., van Werkhoven, H., van Roon, A., van den Ende, C., Hahne, S., de Melker, H., Knol, M., van den Hof, S.
10.1101/2022.07.21.22277831 — Posted: 2022-07-22

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).